Description
Anti-CD79B Antibody, Non-Fucosylated (BioBet-055ZP) is a humanized monoclonal IgG1 antibody against CD79B. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Diffuse large B-cell lymphoma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD79B antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD79B
Full Name
CD79b Molecule
Background
CD79B (CD79b Molecule) is a Protein Coding gene.
Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia, NonBruton Type.
Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineagespecific Markers and Innate Immune System.
Gene Ontology (GO) annotations related to this gene include transmembrane signaling receptor activity.
Alternative Names
CD79b Molecule, CD79B Antigen (Immunoglobulin-Associated Beta), CD79b Molecule, Immunoglobulin-Associated Beta, Immunoglobulin-Associated B29 Protein, B-Cell-Specific Glycoprotein B29, Ig-Beta,
Gene ID
974
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with CD79B include Agammaglobulinemia 6, Autosomal Recessive and Agammaglobulinemia, Non-Bruton Type.
Related Pathways
Its related pathways are B cell receptor signaling pathway (KEGG) and Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
Function
Cooperating with CD79A to initiate the signal transduction cascade activated by the b-cell antigen receptor complex (BCR), which leads to the internalization of the complex, transport to the late endosomes and antigen presentation. Enhancing the phosphorylation of CD79A may be by recruiting kinases that phosphorylate CD79A or by recruiting proteins that bind to CD79A and protect it from dephosphorylation.
Post-translational modifications
Phosphorylated on tyrosine upon B-cell activation by SRC-type Tyr-kinases such as BLK, LYN and SYK.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-055ZP
Description
Polatuzumab vedotin is a CD79b-specific antibody conjugated to the antitumor drug Monomethyl auristatin E.Label.
Antibody Indication
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Lymphoma, Large B-Cell, Diffuse (DLBCL)
